Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

TY - JOUR

T1 - Proton therapy for adults with mediastinal lymphomas

T2 - the International Lymphoma Radiation Oncology Group guidelines

AU - Dabaja, Bouthaina Shbib

AU - Hoppe, Bradford S

AU - Plastaras, John P

AU - Newhauser, Wayne

AU - Rosolova, Katerina

AU - Flampouri, Stella

AU - Mohan, Radhe

AU - Mikhaeel, N George

AU - Kirova, Youlia

AU - Specht, Lena

AU - Yahalom, Joachim

N1 - © 2018 by The American Society of Hematology.

PY - 2018/10/18

Y1 - 2018/10/18

N2 - Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality. Proton therapy may help to reduce the radiation dose to the OARs and reduce toxicities, especially the risks for cardiac morbidity and second cancers. Becauseproton therapymay have some disadvantages, identifying the patients and the circumstances that may benefit the most from proton therapy is important. We present modern guidelines to identify adult lymphoma patients who may derive the greatest benefit from proton therapy, along with an analysis of the advantages and disadvantages of proton treatment. (Blood. 2018;132(16):1635-1646).

AB - Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality. Proton therapy may help to reduce the radiation dose to the OARs and reduce toxicities, especially the risks for cardiac morbidity and second cancers. Becauseproton therapymay have some disadvantages, identifying the patients and the circumstances that may benefit the most from proton therapy is important. We present modern guidelines to identify adult lymphoma patients who may derive the greatest benefit from proton therapy, along with an analysis of the advantages and disadvantages of proton treatment. (Blood. 2018;132(16):1635-1646).

U2 - 10.1182/blood-2018-03-837633

DO - 10.1182/blood-2018-03-837633

M3 - Review

C2 - 30108066

SN - 0006-4971

VL - 132

SP - 1635

EP - 1646

JO - Blood

JF - Blood

IS - 16

ER -